Login to Your Account

Rigel Dented on Asthma Miss; Fostamatinib Decision Looms

By Jennifer Boggs
Managing Editor

Monday, August 26, 2013
Shares of Rigel Pharmaceuticals Inc. were dinged Monday morning after the company said it would discontinue development of Syk inhibitor R343 in allergic asthma following a Phase II miss, another setback for the South San Francisco-based firm’s pipeline.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription